CandlesenseCandlesense
News/Companies/GALT

GALT News

Galectin Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

GALT

(NASDAQ:GALT) NORCROSS, Ga., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that the company management will participate in the H.C. Wainwright 27th Annual Global Investment Conference, taking place September 8-10, 2025 in New York, NY.

September 2, 2025Conference
Read more →

Galectin Therapeutics Q1 EPS $(0.15) Beats $(0.20) Estimate

GALT

May 15, 2025
Read more →

Galectin Therapeutics Issues Presentation Highlighting Its Focused Pipeline, MASH Cirrhosis And Oncology, Developing Galectin-Based Therapeutics To Improve The Lives Of Patients With Chronic Liver Diseases And Cancer

GALT

May 12, 2025
Read more →

HC Wainwright & Co. Reiterates Neutral on Galectin Therapeuticsto Neutral

GALT

April 2, 2025
Read more →

Galectin Therapeutics FY 2024 GAAP EPS $(0.76) Misses $(0.73) Estimate, Cash Balance Of $15.1M

GALT

March 31, 2025
Read more →

Galectin Therapeutics Announces NAVIGATE Trial Results: Belapectin Shows 49.3% Reduction In Varices For Completer Patients In MASH Cirrhosis, Composite Endpoint Not Met

GALT

February 18, 2025
Read more →

Why Is Small Cap Galectin Therapeutics Stock Trading Lower On Friday?

GALT

Galectin Therapeutics' NAVIGATE trial shows belapectin reduces varices in MASH cirrhosis, but falls short of statistical targets; full data due in early 2025.

December 20, 2024
Read more →

Galectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin; Says 'While there was a favorable trend for incidence of varices in the primary end point intent-to-treat population, belapectin did not achieve statistical

GALT

December 20, 2024
Read more →

Galectin Therapeutics Presents 3 Abstracts At The American Association For The Study Of Liver Diseases 2024 Liver Meeting

GALT

November 18, 2024
Read more →

HC Wainwright & Co. Reiterates Buy on Galectin Therapeutics, Maintains $11 Price Target

GALT

November 15, 2024
Read more →

Galectin Therapeutics Q3 2024 GAAP EPS $(0.18) Misses $(0.12) Estimate

GALT

November 14, 2024
Read more →